PURPLE BIOTECH LTD.: Ayrton Capital LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Ayrton Capital LLC has disclosed a stake exceeding 5% in Purple Biotech Ltd. via a Schedule 13G filing with the SEC (accession 0001493152-26-051281). The exact share count and percentage were not specified in the filing headline. The disclosure signals a significant institutional position in the clinical-stage oncology company. Investors will watch for further detail on the size and intent of the holding, and for any subsequent 13D filing should Ayrton adopt an activist stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Purple Biotech Ltd., Ayrton Capital LLC